Drug Trial Radar · NCT02720783
Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary
Last checked: Nov 19, 2026Latest source record: Feb 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Mar 4, 2016
Primary completion
Oct 12, 2016
Study completion Oct 12, 2016
Sponsor
- Lead sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.AIndustry
- Sponsor type
- Industry
- Collaborators
- Cross Research S.A.
- First posted
- Mar 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the local tolerability of the new Econazole/Benzydamine pessary, in comparison with Econazole and Benzydamine stand-alone products and placebo. Pharmacokinetics of the study products after single and multiple applications o.d. for 3 days, overall local and general tolerability, safety and comfort of use will also be evaluated.
Conditions
- Healthy Women
Interventions
Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessaryDrug
Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
Placebo plus Econazole nitrate 150 mg vaginal pessaryDrug
Placebo plus Benzydamine HCl 6 mg vaginal pessaryDrug
Placebo vaginal pessaryDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Local Adverse Drug Reactions (ADRs)Time frame: Up to 7 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CROSS Research S.A., Phase I Unit
Arzo, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.